Molecular Testing in mNSCLC: Digging a Little Deeper Makes All the Difference

Sandip P. Patel, MD


November 22, 2021

Sandip Patel, MD, compares the previous approach to genomic profiling in non–small cell lung cancer as being like finding a street on a map, whereas recent advancements in specificity for various mutations with next-generation sequencing are like finding the correct address. He also recounts an experience with a young patient with NSCLC, despite having no smoking history, to illustrate the importance of testing appropriately. After sending the patient for a DNA plus RNA-based tissue panel, Dr Patel identified a ROS1 mutation and started the patient on entrectinib, which has since resolved his central nervous system metastases.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.